Axsome Therapeutics, Inc. Income Statement

Income Statement Dec2015 Dec2016 Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 50.04M270.60M385.69M
Cost of Revenue 5.20M26.07M33.30M
Gross Profit 44.84M244.53M352.39M
Operating items
Amortization - Intangibles 4.14M6.38M6.39M
Research & Development 58.06M57.95M97.94M187.08M
Selling, General & Administrative 66.65M159.25M323.12M411.36M
Other Operating Expenses -0.28M-0.21M81.36M67.82M
Operating Expenses 124.71M229.84M502.43M666.25M
Operating Income -124.71M-179.80M-231.82M-280.56M
EBIT -124.71M-179.80M-231.82M-280.56M
Non-operating items
Interest & Investment Income -5.70M-7.33M-6.45M-6.57M
Net income details
EBT -130.40M-187.13M-238.28M-287.13M
Tax Provisions 0.96M0.09M
Profit After Tax -130.40M-187.13M-239.24M-287.22M
Income from Continuing Operations -130.40M-187.13M-239.24M-287.22M
Consolidated Net Income -130.40M-187.13M-239.24M-287.22M
Income towards Parent Company -130.40M-187.13M-239.24M-287.22M
Net Income towards Common Stockholders -130.40M-187.13M-239.24M-287.22M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 17.72M19.15M23.67M29.81M34.51M37.34M37.69M43.43M47.32M48.46M
Shares Outstanding (Diluted Average) 40.66M45.43M47.91M
EBITDA -124.71M-179.80M-231.82M-280.56M